Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
JCR Chief Delays Global Licensing Timeline for Lysosomal Storage Disorder Therapies
JCR Pharmaceuticals aims to strike a global licensing deal for its lysosomal storage disease treatments by the end of this fiscal year through March 2021 after picking a partner in the first half, Chairman and President Shin Ashida said on…
To read the full story
Related Article
- JCR Can Strike Global Licensing Deal for Lysosomal Therapies at Least by March-End: Chief
November 4, 2020
- JCR Aims to File Sakigake-Designated Hunter Syndrome Drug in September
May 19, 2020
- JCR Closes ArmaGen Buyout, Gaining IP Rights on Blood-Brain Barrier-Penetrating Technology
April 21, 2020
- JCR Acquiring ArmaGen to Expedite Drug Development for Lysosomal Diseases
March 27, 2020
- JCR to License Lysosome Storage Disease Treatment to Global Player by March 2020: Chairman
May 20, 2019
BUSINESS
- Eisai to Discontinue Tazverik in Japan over Secondary Cancer Risk
March 19, 2026
- BMS, Nikon Eye Full Domestic CAR-T Manufacturing in Japan from 2027
March 19, 2026
- Blenrep, Monjuvi, Zynyz, and More New Drugs Hit Japan Market
March 19, 2026
- Celltrion, CMIC Forge Broad Partnership in Japan Biosimilars Business
March 19, 2026
- J&J Launches Nurse-Led Support Program for Lung Cancer Patients in Japan
March 19, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…